These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 8915309)

  • 1. Drug-induced pseudolymphoma and hypersensitivity syndrome. Two different clinical entities.
    Callot V; Roujeau JC; Bagot M; Wechsler J; Chosidow O; Souteyrand P; Morel P; Dubertret L; Avril MF; Revuz J
    Arch Dermatol; 1996 Nov; 132(11):1315-21. PubMed ID: 8915309
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Misleading or rare cutaneous drug reactions].
    Souteyrand P; d'Incan M; Parent S
    Rev Prat; 2000 Jun; 50(12):1329-33. PubMed ID: 10972075
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Febrile toxiderma in children].
    Larrègue M; Vabres P; Auriol F
    Rev Prat; 1997 Sep; 47(13):1452-7. PubMed ID: 9339026
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drug-induced pseudolymphoma and drug hypersensitivity syndrome (Drug Rash with Eosinophilia and Systemic Symptoms: DRESS).
    Bocquet H; Bagot M; Roujeau JC
    Semin Cutan Med Surg; 1996 Dec; 15(4):250-7. PubMed ID: 9069593
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Cutaneous pseudolymphoma caused by carbamazepine].
    d'Incan M; Mouillet ML; Roger H; Ferrier MC; Buono JP; Déchelotte P; Bignon YJ; Souteyrand P
    Ann Dermatol Venereol; 1998 Jan; 125(1):52-5. PubMed ID: 9747211
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lymphocytic infiltration of the skin (Jessner-Kanof) but not reticular erythematous mucinosis occasionally represents clinical manifestations of Borrelia-associated pseudolymphoma.
    Ziemer M; Eisendle K; Müller H; Zelger B
    Br J Dermatol; 2009 Sep; 161(3):583-90. PubMed ID: 19486001
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cutaneous manifestations in inflammatory bowel diseases: eight cases of psoriasis induced by anti-tumor-necrosis-factor antibody therapy.
    Passarini B; Infusino SD; Barbieri E; Varotti E; Gionchetti P; Rizzello F; Morselli C; Tambasco R; Campieri M
    Dermatology; 2007; 215(4):295-300. PubMed ID: 17911986
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Drug hypersensitive syndrome caused by fluindione].
    Sparsa A; Bédane C; Benazahary H; De Vencay P; Gauthier ML; Le Brun V; Boulinguez S; Loustaud-Ratti V; Soria P; Vidal E; Bonnetblanc JM
    Ann Dermatol Venereol; 2001 Oct; 128(10 Pt 1):1014-8. PubMed ID: 11907960
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vasculitis in erythema induratum of Bazin: a histopathologic study of 101 biopsy specimens from 86 patients.
    Segura S; Pujol RM; Trindade F; Requena L
    J Am Acad Dermatol; 2008 Nov; 59(5):839-51. PubMed ID: 19119100
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bronchiolitis obliterans-organizing pneumonia: an Italian experience.
    Cazzato S; Zompatori M; Baruzzi G; Schiattone ML; Burzi M; Rossi A; Ratta L; Terzuolo G; Falcone F; Poletti V
    Respir Med; 2000 Jul; 94(7):702-8. PubMed ID: 10926343
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tissue eosinophilia as an indicator of drug-induced cutaneous small-vessel vasculitis.
    Bahrami S; Malone JC; Webb KG; Callen JP
    Arch Dermatol; 2006 Feb; 142(2):155-61. PubMed ID: 16490843
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Baboon syndrome resulting from systemic drugs: is there strife between SDRIFE and allergic contact dermatitis syndrome?
    Häusermann P; Harr T; Bircher AJ
    Contact Dermatitis; 2004; 51(5-6):297-310. PubMed ID: 15606657
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Usefulness of skin testing in cutaneous drug eruptions in routine practice.
    Tchen T; Reguiaï Z; Vitry F; Arnoult E; Grange A; Florent G; Bernard P
    Contact Dermatitis; 2009 Sep; 61(3):138-44. PubMed ID: 19780771
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lymphomatoid drug reaction secondary to methylphenidate hydrochloride.
    Welsh JP; Ko C; Hsu WT
    Cutis; 2008 Jan; 81(1):61-4. PubMed ID: 18306850
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cutaneous pseudolymphoma induced by Cimicifuga racemosa.
    Meyer S; Vogt T; Obermann EC; Landthaler M; Karrer S
    Dermatology; 2007; 214(1):94-6. PubMed ID: 17191056
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Cutaneous lymphoid hyperplasia (pseudolymphoma) on the red dye of a tattoo].
    Gardair Bouchy C; Kerdraon R; Kluger N; Armingaud P; Wakosa A; Estève E
    Ann Pathol; 2013 Aug; 33(4):273-7. PubMed ID: 23954123
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Drug eruptions: approaching the diagnosis of drug-induced skin diseases.
    Nigen S; Knowles SR; Shear NH
    J Drugs Dermatol; 2003 Jun; 2(3):278-99. PubMed ID: 12848112
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Carbamazepine-induced pseudolymphoma with CD-30 positive cells.
    Nathan DL; Belsito DV
    J Am Acad Dermatol; 1998 May; 38(5 Pt 2):806-9. PubMed ID: 9591791
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cutaneous lymphoid hyperplasia and reactive lymphadenopathy induced by hepatitis B vaccination.
    Atalar H; Sarifakioglu E; Dener C; Yanik B; Koktener A; Bayrak R
    Eur J Dermatol; 2008; 18(2):188-9. PubMed ID: 18424381
    [No Abstract]   [Full Text] [Related]  

  • 20. Increased drug reactions in HIV-1-positive patients: a possible explanation based on patterns of immune dysregulation seen in HIV-1 disease. The Military Medical Consortium for the Advancement of Retroviral Research (MMCARR).
    Smith KJ; Skelton HG; Yeager J; Ledsky R; Ng TH; Wagner KF
    Clin Exp Dermatol; 1997 May; 22(3):118-23. PubMed ID: 9425690
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.